• Login
    View Item 
    •   Home
    • The Christie Research Publications Repository
    • All Christie Publications
    • View Item
    •   Home
    • The Christie Research Publications Repository
    • All Christie Publications
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Browse

    All of ChristieCommunitiesTitleAuthorsIssue DateSubmit DateSubjectsThis CollectionTitleAuthorsIssue DateSubmit DateSubjects

    My Account

    LoginRegister

    Local Links

    The Christie WebsiteChristie Library and Knowledge Service

    Statistics

    Display statistics

    Radiotherapy after chemotherapy for metastatic seminoma--a diminishing role. MRC Testicular Tumour Working Party.

    • CSV
    • RefMan
    • EndNote
    • BibTex
    • RefWorks
    Authors
    Duchesne, G
    Stenning, S
    Aass, N
    Mead, G
    Fosså, S
    Oliver, R
    Horwich, A
    Read, G
    Roberts, I
    Rustin, G
    Cullen, M
    Kaye, Stan B
    Harland, S
    Cook, P
    Show allShow less
    Affiliation
    Department of Oncology, UCL Medical School, Middlesex Hospital, London, U.K.
    Issue Date
    1997-05
    
    Metadata
    Show full item record
    Abstract
    In a retrospective study, data from 302 patients with metastatic testicular seminoma treated with chemotherapy between 1978 and 1990 in 10 European centres were analysed to evaluate the role, if any, of postchemotherapy treatment with irradiation. The primary endpoint of this study was the progression-free survival rate after chemotherapy with or without additional radiotherapy. This was related to the type of primary chemotherapy, sites and sizes of pre- and postchemotherapy masses, the extent of surgical resection after chemotherapy and the use of radiotherapy. 174 patients had residual disease at the end of chemotherapy. The most important prognostic factors for progression were the presence of any visceral metastases or raised LDH prechemotherapy, and the presence of residual disease at visceral sites after chemotherapy. Approximately half the patients with residual masses underwent postchemotherapy radiotherapy, with selection based predominantly on institutional practice. In patients receiving platinum-based chemotherapy, no significant difference was detected in progression-free survival whether or not radiotherapy was employed. Patients receiving BEP (bleomycin, etoposide and cisplatin) had a progression-free survival rate of 88% (95% CI, 80-96%) uninfluenced by postchemotherapy radiotherapy. In patients with residual masses confined to the abdomen after platinum-based chemotherapy, the absolute benefit to radiotherapy was estimated to be 2.3%. The potential benefit of postchemotherapy radiotherapy is minimal, and so it is concluded that the use of adjuvant radiotherapy to residual masses after platinum-based chemotherapy for metastatic seminoma is unnecessary.
    Citation
    Radiotherapy after chemotherapy for metastatic seminoma--a diminishing role. MRC Testicular Tumour Working Party. 1997, 33 (6):829-35 Eur J Cancer
    Journal
    European Journal of Cancer
    URI
    http://hdl.handle.net/10541/94751
    DOI
    10.1016/S0959-8049(97)00033-6
    PubMed ID
    9291801
    Type
    Article
    Language
    en
    ISSN
    0959-8049
    ae974a485f413a2113503eed53cd6c53
    10.1016/S0959-8049(97)00033-6
    Scopus Count
    Collections
    All Christie Publications

    entitlement

    Related articles

    • Management of testicular seminoma advanced disease. Report on 14 cases and review of the literature.
    • Authors: Porcaro AB, Antoniolli SZ, Maffei N, Beltrami P, Bassetto MA, Curti P
    • Issue date: 2002 Jun
    • [Management of advanced seminoma: retrospective study of 96 patients].
    • Authors: Bompas E, Fléchon A, Biron P, Droz JP
    • Issue date: 2002 Oct
    • Residual mass following chemotherapy of seminoma.
    • Authors: Horwich A, Paluchowska B, Norman A, Huddart R, Nicholls J, Fisher C, Husband J, Dearnaley DP
    • Issue date: 1997 Jan
    • Prognostic analysis of Japanese men with metastatic germ cell tumors showing favorable response to bleomycin, etoposide and cisplatin as first-line chemotherapy.
    • Authors: Kumano M, Miyake H, Hara I, Muramaki M, Takenaka A, Fujisawa M
    • Issue date: 2007 Dec
    • Radiotherapy treatment planning for testicular seminoma.
    • Authors: Wilder RB, Buyyounouski MK, Efstathiou JA, Beard CJ
    • Issue date: 2012 Jul 15
    DSpace software (copyright © 2002 - 2021)  DuraSpace
    Quick Guide | Contact Us
    Open Repository is a service operated by 
    Atmire NV
     

    Export search results

    The export option will allow you to export the current search results of the entered query to a file. Different formats are available for download. To export the items, click on the button corresponding with the preferred download format.

    By default, clicking on the export buttons will result in a download of the allowed maximum amount of items.

    To select a subset of the search results, click "Selective Export" button and make a selection of the items you want to export. The amount of items that can be exported at once is similarly restricted as the full export.

    After making a selection, click one of the export format buttons. The amount of items that will be exported is indicated in the bubble next to export format.